PULMATRIX INC (PULM)
US74584P3010 - Common Stock
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROIC, BERY, PULM on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, ALVR, PULM, ENTO on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM, LBRDA, ENTO, LLYVA on Behalf of Shareholders
PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, LBRDA, PULM, ENTO on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders
Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
PULM Stock Earnings: Pulmatrix Reported Results for Q2 2024
Pulmatrix just reported results for the second quarter of 2024.
PULM Stock Earnings: Pulmatrix Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pulmatrix (NASDAQ:PULM) just reported results for the second quarter of 2024.Pu...
Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
PULM Stock Earnings: Pulmatrix Reported Results for Q1 2024
Pulmatrix just reported results for the first quarter of 2024.
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
PULM Stock Earnings: Pulmatrix Beats EPS, Beats Revenue for Q4 2023
PULM stock results show that Pulmatrix beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
PULM Stock Earnings: Pulmatrix Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pulmatrix (NASDAQ:PULM) just reported results for the fourth quarter of 2023.Pu...
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious...
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Supports World Asthma Day 2023
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary...
Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease...
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology
/PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease...
PULM stock drops on early data for inhaled migraine therapy (NASDAQ:PULM)
Pulmatrix, Inc. (PULM) dropped ~18% in the morning hours Wednesday after announcing topline results from a Phase 1 trial for its migraine therapy PUR3100. Read the full story here.